Unlabelled: The natural history of hepatitis B virus (HBV) infection in a U.S. population has not been well described. We identified the causes of death in 6,689 health plan members infected with HBV who were followed between March 1, 1996 and December 31, 2005. Causes of death were grouped into HBV-related (subdivided into decompensated cirrhosis [DCC] and hepatocellular carcinoma [HCC]), cancer, cardiovascular, and other/unknown. The study cohort included 3,244 females and 3,445 males; 68.3% were of Asian-Pacific Islander (API) descent, 11.8% were white (non-Hispanic), and 19.9% were of other or unknown race. Exposure to HBV antivirals and preexisting comorbidities were uncommon. Males had higher overall 10-year death rates than females, both for total deaths (8.9% versus 4.1%) and for HBV-related deaths (4.8% versus 1.2%). The death rate rose markedly with increasing age, and approximately 40% of all deaths in subjects over the age of 40 were HBV related. The death rate from HCC was twice that of DCC. HCC deaths represented 70% of cancer deaths in males and 37% in females. On multivariable analysis, when subjects with antecedent HCC and DCC were excluded, the only significant predictor of HBV mortality in both sexes was age.
Conclusion: HBV was the cause of death in over 40% of those who died during the study, and the mortality increased markedly with increasing age over 40 in males and over 50 in females. HBV-related mortality was four times more common in males than in females and was as common in non-Asians as in those of API origin. HBV-related deaths were twice as common from HCC as from DCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hep.26110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study.
J Comp Eff Res
December 2024
Loma Linda University, School of Medicine, Loma Linda, CA, USA.
Article Synopsis
- * The research analyzed data from over 14,800 patients diagnosed with NASH, categorizing them by severity levels of liver disease and calculating healthcare costs and resource utilization before and after diagnosis.
- * Findings showed that annual healthcare costs significantly increased with disease severity, with patients who progressed from NASH to more severe states incurring notably higher expenses and hospitalizations compared to those who did not progress.
Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives.
Clinicoecon Outcomes Res
October 2024
Department of Drug Sciences, University of Pavia, Pavia, Italy.
Article Synopsis
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rising health issue in Italy, with the study evaluating its economic burden on the National Healthcare Service.
- Utilizing an Excel model, researchers compared healthcare costs and complications associated with MASLD against a similar population without it, revealing significant financial and mortality impacts.
- The study estimates that MASLD could cost the Italian healthcare system over €12 billion annually and result in approximately 13,438 extra deaths, highlighting the need for lifestyle changes and future pharmaceutical interventions.
Progression from Non-alcoholic Steatohepatitis to Advanced Liver Diseases and Mortality Among Medicare Patients.
Adv Ther
November 2024
Loma Linda University, Loma Linda, CA, USA.
Introduction: Non-alcoholic steatohepatitis (NASH) may progress to more advanced liver disease. This study aimed to characterize NASH progression and mortality in the Medicare population.
Methods: Patients with NASH in 100% Medicare fee-for-service claims accrued from 2015-2021 who were ≥ 66 years old at index diagnosis, continuously enrolled for ≥ 12 months prior to and ≥ 6 months following index (unless death), and had no evidence of other causes of liver disease were included.
Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D.
Gastroenterol Hepatol
March 2025
Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
Article Synopsis
- * Using an economic model, the study projected lifetime liver complications and costs for both treatments in a hypothetical cohort of 3,882 CHD patients, focusing on serious complications like decompensated cirrhosis, hepatocellular carcinoma, and death.
- * Results showed that bulevirtide significantly reduced complications and associated costs by approximately €11.8 million compared to PEG-IFN-α, suggesting it is a more efficient treatment option
Impact of Direct-acting Antivirals on Hepatocellular Carcinoma and Mortality Among Medicaid Beneficiaries With Hepatitis C.
Med Care
August 2023
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy.
Objective: The effects of all-oral direct-acting antivirals (DAAs) on hepatocellular carcinoma (HCC) and liver-related and all-cause mortality were assessed among Medicaid beneficiaries with hepatitis C virus (HCV).
Subjects: This cohort study used 2013-2019 Arizona Medicaid data from beneficiaries with HCV aged 18-64 years.
Methods: Risks of HCC and liver-related and all-cause mortality were compared between patients with or without DAA treatment, stratified by liver disease severity, using inverse probability of treatment weighted multivariable Cox proportional hazards regression models.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!